Viral Inactivation Market

Major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).

There is a high degree of consolidation in the viral inactivation market, with few large players dominating the market. High degree of consolidation is major barriers for new entrants in this market. Small and medium-sized players account for a small share of the market and their business interests remain concentrated in local markets across emerging geographies. Merck KGaA (Germany), Danaher Corporation (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), and Parker Hannifin (U.S.) are the leaders in this market. The combined market share of these five companies, far exceed that of all other players. Overall, about 75% of the global viral inactivation market will be dominated by these companies in 2015. Furthermore, acquisitions by market leaders in this field have strengthened their market positions and have served to further consolidate the market.

Acquisition and expansions were the two most important growth strategies employed in this market. An analysis of market developments between 2012 and 2016 revealed that expansion was the most adopted growth strategy employed by the market leaders in this period. For instance, in October 2014, SGS Life Science Services completed the expansion of biologics testing facility in Glasgow, UK. The 500 square meter expansion, with a staff of 45 personnel will offer a full range of validated bioanalytical methods for testing of biologics, viral vaccines, and gene & cell therapies. This strategy was adopted by Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), SGS S.A. (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).

The other important growth strategies were acquisition, implemented to gain immediate technological competency and widen geographic presence. For instance, in September 2014, Merck KGaA (Germany) completed the acquisition of Sigma-Aldrich Corporation. This acquisition expanded the company’s business in various geographies and enhanced its product portfolio. This strategy was adopted by Charles River Laboratories International, Inc. (U.S.), Merck KGaA (Germany), Parker Hannifin Corporation (U.S.), SGS SA (Switzerland), Sartorius AG (Germany), and Danaher Corporation (U.S.).

Related Reports:

Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) - Global Forecast to 2021

Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: [email protected]